OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools.
OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc.
OpZira’s product portfolio includes:
- AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the first functional signs of retinal disease. AdaptDx Pro is available in the U.S.
- NOVA™ Vision Testing System – A robust electrophysiology platform providing objective assessments of the entire visual and neuro-visual pathway. The Visual Evoked Potential (VEP) module is available in the U.S. and select international markets, while the Electroretinography (ERG) module is available outside the U.S.
“Building on the LumiThera team’s success in developing the Valeda treatment for early to intermediate dry AMD patients, the OpZira technologies may provide early detection and ongoing monitoring which are important for optimizing patient outcomes,” stated Eleonora Lad, MD, PhD, Duke University Medical Center. “Now that there are approved treatment options for dry AMD, having tools that provide objective data to help determine when and how often to treat patients is critical.”
“OpZira was founded to bridge the gap between groundbreaking research and practical clinical tools,” said Clark Tedford, PhD, President & CEO of OpZira. “Our mission is to give eye care professionals the technology they need to detect ocular diseases earlier and monitor them more effectively.”
About OpZira
OpZira, Inc. is a forward-thinking ophthalmic medical device company founded on a legacy of research excellence. The company delivers innovative technologies designed to enhance the detection and monitoring of ocular disease. For more information, visit OpZira.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903785229/en/
Contacts
marketing@opzira.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press Release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 14:03:00 CET | Press Release
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20
Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 14:00:00 CET | Press Release
Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe rapidly transitions away from fossil fuels, the demand for residential heat pumps is growing in parallel with ambitious sustainabil
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press Release
Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower cost in payments, so with the support of Visa, we are evaluating how this technology could fit into our broader strategy to deliver meaningful value to ou
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom